

## Clinical Policy: Ocrelizumab (Ocrevus)

Reference Number: CP.PHAR.335

Effective Date: 05.01.17

Last Review Date: 05.20

Line of Business: Commercial, HIM, Medicaid

[Revision Log](#)

See [Important Reminder](#) at the end of this policy for important regulatory and legal information.

### Description

Ocrelizumab (Ocrevus<sup>TM</sup>) is a CD20-directed cytolytic antibody.

### FDA Approved Indication(s)

Ocrevus is indicated for the treatment of:

- Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults
- Primary progressive MS, in adults

### Policy/Criteria

*Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.*

It is the policy of health plans affiliated with Centene Corporation<sup>®</sup> that Ocrevus is **medically necessary** when the following criteria are met:

#### I. Initial Approval Criteria

##### A. Multiple Sclerosis (must meet all):

1. Diagnosis of one of the following (a, b, c, or d):
  - a. Clinically isolated syndrome, and member is contraindicated to both or has experienced clinically significant adverse effects to one of the following at up to maximally indicated doses: an interferon-beta agent (Avonex<sup>®</sup>, Betaseron<sup>®</sup>, Rebif<sup>®</sup>, or Plegridy<sup>®</sup>), glatiramer (Copaxone<sup>®</sup>, Glatopa<sup>®</sup>);
  - b. Relapsing-remitting MS, and failure of two of the following at up to maximally indicated doses, unless clinically significant adverse effects are experienced or all are contraindicated: Aubagio<sup>®</sup>, Tecfidera<sup>®</sup>, Gilenya<sup>TM</sup>, an interferon-beta agent (Avonex, Betaseron, Rebif, or Plegridy), glatiramer (Copaxone<sup>®</sup>, Glatopa<sup>®</sup>), Mayzent<sup>®</sup>;  
*\*Prior authorization is required for all disease modifying therapies for MS*
  - c. Secondary progressive MS
  - d. Primary progressive MS;
2. Prescribed by or in consultation with a neurologist;
3. Age ≥ 18 years;
4. Ocrevus is not prescribed concurrently with other disease modifying therapies for MS (see Appendix D);
5. At the time of request, member does not have active hepatitis B infection (positive results for hepatitis B surface antigen and anti-hepatitis B virus tests);

6. Dose does not exceed the following:
  - a. Initial dose: 300 mg, followed by a second 300 mg dose 2 weeks later;
  - b. Maintenance dose: 600 mg every 6 months.

**Approval duration:**

**Medicaid/HIM** – 6 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**B. Other diagnoses/indications**

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**II. Continued Therapy**

**A. Multiple Sclerosis (must meet all):**

1. Currently receiving medication via Centene benefit or member has previously met initial approval criteria;
2. Member is responding positively to therapy;
3. Ocrevus is not prescribed concurrently with other disease modifying therapies for MS (*see Appendix D*);
4. If request is for a dose increase, new dose does not exceed 600 mg every 6 months.

**Approval duration:**

**Medicaid/HIM** – 12 months

**Commercial** – 6 months or to the member's renewal date, whichever is longer

**B. Other diagnoses/indications (must meet 1 or 2):**

1. Currently receiving medication via Centene benefit and documentation supports positive response to therapy.

**Approval duration: Duration of request or 6 months (whichever is less); or**

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid.

**III. Diagnoses/Indications for which coverage is NOT authorized:**

- A. Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – CP.CPA.09 for commercial, HIM.PHAR.21 for health insurance marketplace, and CP.PMN.53 for Medicaid or evidence of coverage documents.

**IV. Appendices/General Information**

*Appendix A: Abbreviation/Acronym Key*

FDA: Food and Drug Administration

MS: multiple sclerosis

*Appendix B: Therapeutic Alternatives*

*This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.*

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Aubagio <sup>®</sup> (teriflunomide)	7 mg or 14 mg PO QD	14 mg/day
Avonex <sup>®</sup> , Rebif <sup>®</sup> (interferon beta-1a)	Avonex: 30 mcg IM Q week Rebif: 22 mcg or 44 mcg SC TIW	Avonex: 30 mcg/week Rebif: 44 mcg TIW
Plegridy <sup>®</sup> (peginterferon beta-1a)	125 mcg SC Q2 weeks	125 mcg/2 weeks
Betaseron <sup>®</sup> (interferon beta-1b)	250 mcg SC QOD	250 mg QOD
glatiramer acetate (Copaxone <sup>®</sup> , Glatopa <sup>®</sup> )	20 mg SC QD or 40 mg SC TIW	20 mg/day or 40 mg TIW
Gilenya <sup>™</sup> (fingolimod)	0.5 mg PO QD	0.5 mg/day
Tecfidera <sup>®</sup> (dimethyl fumarate)	120 mg PO BID for 7 days, followed by 240 mg PO BID	480 mg/day
Mayzent <sup>®</sup> (siponimod)	<i>All patients:</i> Day 1 and 2: 0.25 mg PO QD Day 3: 0.5 mg PO QD Day 4: 0.75 mg PO QD  <i>CYP2C9 genotypes *1/*1, *1/*2, or *2/*2:</i> Day 5: 1.25 mg PO QD Day 6 and onward: 2 mg PO QD  <i>CYP2C9 genotypes *1/*3 or *2/*3:</i> Day 5 and onward: 1 mg PO QD	2 mg/day

*Therapeutic alternatives are listed as Brand name<sup>®</sup> (generic) when the drug is available by brand name only and generic (Brand name<sup>®</sup>) when the drug is available by both brand and generic.*

*Appendix C: Contraindications/Boxed Warnings*

- Contraindication(s): active hepatitis B virus infection; history of life-threatening infusion reaction to Ocrevus
- Boxed warning(s): none reported

*Appendix D: General Information*

- Disease-modifying therapies for MS are: glatiramer acetate (Copaxone<sup>®</sup>, Glatopa<sup>®</sup>), interferon beta-1a (Avonex<sup>®</sup>, Rebif<sup>®</sup>), interferon beta-1b (Betaseron<sup>®</sup>, Extavia<sup>®</sup>), peginterferon beta-1a (Plegridy<sup>®</sup>), dimethyl fumarate (Tecfidera<sup>®</sup>), diroximel fumarate (Vumerity<sup>™</sup>), fingolimod (Gilenya<sup>™</sup>), teriflunomide (Aubagio<sup>®</sup>), alemtuzumab (Lemtrada<sup>®</sup>), mitoxantrone (Novantrone<sup>®</sup>), natalizumab (Tysabri<sup>®</sup>), ocrelizumab (Ocrevus<sup>™</sup>), cladribine (Mavenclad<sup>®</sup>), and siponimod (Mayzent<sup>®</sup>).

- Although many disease-modifying therapies for MS are FDA-labeled for CIS, only the interferon products, glatiramer, and Aubagio have demonstrated any efficacy in decreasing the risk of conversion to MS compared to placebo. This is supported by the AAN 2018 MS guidelines.

## V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
Relapsing and primary progressive MS	Initial 300 mg IV infusion with a second 300 mg IV infusion two weeks later, followed by subsequent doses of 600 mg via IV infusion every 6 months	600 mg/6 months

## VI. Product Availability

Single-dose vial: 300 mg/10 mL

## VII. References

- Ocrevus Prescribing Information. South San Francisco, CA: Genentech, Inc; November 2019. Available at [www.ocrevus.com](http://www.ocrevus.com). Accessed January 27, 2020.
- Costello K, Halper J, Kalb R, Skutnik L, Rapp R. The use of disease-modifying therapies in multiple sclerosis, principles and current evidence – a consensus paper by the Multiple Sclerosis Coalition. Updated June 2019. Accessed January 27, 2020.
- Rae-Grant A, Day GS, Marrie RA, et al. Practice guideline recommendations summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology. *Neurology*. 2018; 90(17): 777-788. Full guideline available at: <https://www.aan.com/Guidelines/home/GetGuidelineContent/904>.

Reviews, Revisions, and Approvals	Date	P&T Approval Date
New policy.	04.17	04.17
Changed requirement of failure of glatiramer acetate, Tecfidera, or Gilenya, to the following: Tecfidera or Gilenya and either an interferon-beta agent or glatiramer; or Tecfidera and Gilenya.	05.17	
Age requirement added. Removed MRI requirement. Removed “Appendix B- general information.”	07.17	08.17
2Q 2018 annual review: no significant changes; references reviewed and updated.	01.05.18	05.18
2Q 2019 annual review: no significant changes; specified that generic forms of glatiramer are preferred; references reviewed and updated.	02.06.19	05.19
RT4: added coverage for CIS and SPMS per updated FDA labeling; references reviewed and updated.	08.02.19	
Updated RRMS re-directions and added CIS re-directions per SDC and prior clinical guidance; added COM and HIM lines of business (CP.CPA.307 and HIM.PA.SP31 retired)	01.21.20	

Reviews, Revisions, and Approvals	Date	P&T Approval Date
2Q 2020 annual review: modified CIS re-direction to include glatiramer to per SDC; references reviewed and updated.	01.27.20	05.20

### **Important Reminder**

This clinical policy has been developed by appropriately experienced and licensed health care professionals based on a review and consideration of currently available generally accepted standards of medical practice; peer-reviewed medical literature; government agency/program approval status; evidence-based guidelines and positions of leading national health professional organizations; views of physicians practicing in relevant clinical areas affected by this clinical policy; and other available clinical information. The Health Plan makes no representations and accepts no liability with respect to the content of any external information used or relied upon in developing this clinical policy. This clinical policy is consistent with standards of medical practice current at the time that this clinical policy was approved. “Health Plan” means a health plan that has adopted this clinical policy and that is operated or administered, in whole or in part, by Centene Management Company, LLC, or any of such health plan’s affiliates, as applicable.

The purpose of this clinical policy is to provide a guide to medical necessity, which is a component of the guidelines used to assist in making coverage decisions and administering benefits. It does not constitute a contract or guarantee regarding payment or results. Coverage decisions and the administration of benefits are subject to all terms, conditions, exclusions and limitations of the coverage documents (e.g., evidence of coverage, certificate of coverage, policy, contract of insurance, etc.), as well as to state and federal requirements and applicable Health Plan-level administrative policies and procedures.

This clinical policy is effective as of the date determined by the Health Plan. The date of posting may not be the effective date of this clinical policy. This clinical policy may be subject to applicable legal and regulatory requirements relating to provider notification. If there is a discrepancy between the effective date of this clinical policy and any applicable legal or regulatory requirement, the requirements of law and regulation shall govern. The Health Plan retains the right to change, amend or withdraw this clinical policy, and additional clinical policies may be developed and adopted as needed, at any time.

This clinical policy does not constitute medical advice, medical treatment or medical care. It is not intended to dictate to providers how to practice medicine. Providers are expected to exercise professional medical judgment in providing the most appropriate care, and are solely responsible for the medical advice and treatment of members. This clinical policy is not intended to recommend treatment for members. Members should consult with their treating physician in connection with diagnosis and treatment decisions.

Providers referred to in this clinical policy are independent contractors who exercise independent judgment and over whom the Health Plan has no control or right of control. Providers are not agents or employees of the Health Plan.

This clinical policy is the property of the Health Plan. Unauthorized copying, use, and distribution of this clinical policy or any information contained herein are strictly prohibited. Providers, members and their representatives are bound to the terms and conditions expressed herein through the terms of their contracts. Where no such contract exists, providers, members and their representatives agree to be bound by such terms and conditions by providing services to members and/or submitting claims for payment for such services.

**Note:**

**For Medicaid members**, when state Medicaid coverage provisions conflict with the coverage provisions in this clinical policy, state Medicaid coverage provisions take precedence. Please refer to the state Medicaid manual for any coverage provisions pertaining to this clinical policy.

©2017 Centene Corporation. All rights reserved. All materials are exclusively owned by Centene Corporation and are protected by United States copyright law and international copyright law. No part of this publication may be reproduced, copied, modified, distributed, displayed, stored in a retrieval system, transmitted in any form or by any means, or otherwise published without the prior written permission of Centene Corporation. You may not alter or remove any trademark, copyright or other notice contained herein. Centene® and Centene Corporation® are registered trademarks exclusively owned by Centene Corporation.